Categories: Mobile Technology

Stallergenes Greer and Aptar Pharma Announce Partnership

“We are pleased to combine Aptar Pharma’s Digital Health ecosystem with Stallergenes Greer’s knowledge and leading position in AIT to further improve the treatment journey of patients who suffer from allergies,” said Sai Shankar, Vice President, Global Digital Healthcare Systems, Aptar Pharma.
Share the News
FacebookFacebook

Stallergenes Greer, a global healthcare company specializing in allergen immunotherapy (AIT), today announced that the company has entered into an exclusive partnership with Aptar Pharma, a global leader in drug delivery systems, services, and active material science solutions, for the development of the first of its kind connected device and companion mobile app for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions.

“This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer’s investments in innovation to provide a large range of precise personalized allergen immunotherapy options adapted to the individual needs and lifestyle of patients. Stallergenes Greer is well advanced on its digital transformation journey and will continue to develop its e-health offering for the benefit of all stakeholders,” stated Dominique Pezziardi, General manager France, Belgium and Luxembourg, Global Head of Pricing and Market Access.

Non-adherence to an AIT schedule and premature discontinuation of treatment remain a challenge in AIT management. This innovative, easy-to-use connected device will contribute to improving dose compliance and adherence, thus optimising treatment outcomes.

The development work is being undertaken by Aptar Pharma’s Digital Health group, which has capabilities and expertise in device and software development. The product will leverage Aptar Pharma’s Cohero platform, which will be tailored specifically for this use.

“We are pleased to combine Aptar Pharma’s Digital Health ecosystem with Stallergenes Greer’s knowledge and leading position in AIT to further improve the treatment journey of patients who suffer from allergies,” said Sai Shankar, Vice President, Global Digital Healthcare Systems, Aptar Pharma.

The newly developed connected device should be available in France in 2022 and will be progressively rolled-out in Stallergenes Greer’s markets.

This innovation further illustrates Stallergenes Greer’s commitment to build on precision medicine and personalized healthcare which cater to the needs of both patients and the medical community.